3.4-Dipivaloxy-α-<(isopropylamino)methyl>benzylalkohol | 53264-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3.4-Dipivaloxy-α-<(isopropylamino)methyl>benzylalkohol
• 英文别名: [2-(2,2-Dimethylpropanoyloxy)-4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl] 2,2-dimethylpropanoate;hydrochloride
• CAS: 53264-07-6
• 化学式: C₂₁H₃₃NO₅*ClH
• 分子量: 415.958
• InChiKey: JYFCYYIGLFIFGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.04
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  84.9
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• EP2001833A1
  申请人：——

  公开号：EP2001833A1

  公开（公告）日：2008-12-17
• USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS
  申请人：National Research Council of Canada

  公开号：EP2117524B1

  公开（公告）日：2019-08-14
• ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES
  申请人：Konishi Yasuo

  公开号：US20110060045A1

  公开（公告）日：2011-03-10

  The invention disclosed relates to the use of anti-glycation agents of formula (I), wherein X represents NR 7 , wherein R 7 represents hydrogen atom or an acyl group derived from a linear, branched or cyclic C 1-10 aliphatic acid or a C 6-10 aromatic acid, R 1 represents hydrogen atom, NH 2 , or a linear, branched or cyclic C 1-10 alkyl which may be substituted with a C 6-10 aromatic group, R 2 represents hydrogen atom, a linear, branched or cyclic C 1-10 alkyl, or COOH group, R′ 2 represents hydrogen atom or a linear, branched or cyclic C 1-10 alkyl group, R 3 represents hydrogen atom, ═O, OR 8 , SR 8 , or NR 8 R 9 , wherein R 8 and R 9 represent hydrogen atom, a linear, branched or cyclic C 1-10 alkyl, or an acyl group derived from a linear or branched C 1-10 aliphatic acid or a C 6-10 aromatic acid, provided that R 8 and R 9 are not both an acyl group, R 4 and R 5 each independently represents OH, NH 2 , or SH, R 6 represents hydrogen, F, Cl, Br, I, OR 10 , or SR 10 , wherein R 10 represents hydrogen or an acyl group derived from a linear or branched C 1-10 aliphatic acid or a C 6-10 aromatic acid, R 6 may be present more than once and each R 6 may be the same or different, a physiologically tolerated salt, prodrug, physiologically functional derivative or mixture thereof, such as (S)-isoproterenol, and its prodrug, (S)-isoproterenol dipivalate hydrochloride on the initiation of diabetic cataracts. (S)-Isoproterenol is a strong anti-glycation agent with an in vitro IC 50 value of 16.8±0.8 μM. (S)-isoproterenol dipivalate hydrochloride was prepared in eye drop form at 0.1% concentration and was applied to diabetic rats twice a day up to 30 weeks. No cataract was observed in non-diabetic rats with or without treatment of the prodrug. In diabetic rats without treatment of the prodrug (group III), 88% of eyes got cataract at 8.6±1.5 weeks. In diabetic rats with treatment of the prodrug, only 53% of the eyes initiated cataract at 8.6±1.2 weeks, and the remaining 26% of the eyes prolonged the initiation to 17.1±3.1 weeks. Furthermore, no cataract was observed in 21% of the eyes even at 30 weeks.
• US9351947B2
  申请人：——

  公开号：US9351947B2

  公开（公告）日：2016-05-31
• [EN] ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS CONTRE LA CATARACTE DIABÉTIQUE ET UTILISATIONS DE CEUX-CI
  申请人：CA NAT RESEARCH COUNCIL

  公开号：WO2007109882A1

  公开（公告）日：2007-10-04

  [EN] The invention disclosed relates to the use of anti-glycation agents, such as (S)-isoproterenol, and its prodrug, (S)-isoproterenol dipivalate hydrochloride on the initiation of diabetic cataracts. (S)-Isoproterenol is a strong anti-glycation agent with an in vitro IC₅₀ value of 16.8 ± 0.8 µM. (S)-isoproterenol dipivalate hydrochloride was prepared in eye drop form at 0.1% concentration and was applied to diabetic rats twice a day up to 30 weeks. No cataract was observed in non-diabetic rats with or without treatment of the prodrug. In diabetic rats without treatment of the prodrug (group III), 88% of eyes got cataract at 8.6 ± 1.5 weeks. In diabetic rats with treatment of the prodrug, only 53% of the eyes initiated cataract at 8.6 ± 1.2 weeks, and the remaining 26% of the eyes prolonged the initiation to 17.1 ± 3.1 weeks. Furthermore, no cataract was observed in 21% of the eyes even at 30 weeks.
  [FR] L'invention concerne l'utilisation d'agents inhibiteurs de la glycation, tels que le (S)-isoprotérénol et son promédicament, le chlorhydrate de dipivalate de (S)-isoprotérénol, sur le développement initial de cataractes diabétiques. Le (S)-isoprotérénol est un puissant agent inhibiteur de la glycation présentant une valeur de IC₅₀ in vitro <